It is therefore collectively suggested that PR-ASG may protect pancreatic β-cells via enhancement of an IGF-1 dependent autocrine system, leading to subsequent activation of an IGF-1 dependent–defense system, which, together with HTase activation, may be useful in the treatment of oxidative stress and its complications in diabetes. Here, IGF1 is linked to diabetes mellitus.